Literature DB >> 27265366

Impaired metabolic profile is a predictor of capillary rarefaction in a population of hypertensive and normotensive individuals.

Areti Triantafyllou1, Panagiota Anyfanti2, Georgios Triantafyllou1, Xenophon Zabulis3, Spyros Aslanidis4, Stella Douma1.   

Abstract

Capillary rarefaction is typically encountered in essential hypertension, yet identification of factors interfering with this phenomenon remains substantially underinvestigated. We examined whether components of metabolic profile (dyslipidemia, insulin resistance), inflammatory (high-sensitivity C-reactive protein, high-sensitivity C-reactive protein), and angiogenic (vascular endothelial growth factor) factors are implicated in this phenomenon in a population of newly diagnosed, never-treated hypertensive patients and normotensive controls. Nailfold capillary density was estimated with nailfold capillaroscopy using specifically designed software. A total of 159 individuals, 93 hypertensives, and 66 normotensives were included. Nailfold capillary density was lower among hypertensives compared to normotensives (146.4 ± 31.0 vs. 155.4 ± 26.9, respectively; P = .047). In the total population, capillary density significantly correlated with high-density lipoprotein (HDL) (r = 0.232; P = .003), HDL/low-density lipoprotein ratio (r = 0.175; P = .025), age (r = 0.236; P = .003), but neither with vascular endothelial growth factor or high-sensitivity C-reactive protein. An inverse association was found with body mass index (r = -0.174; P = .029), insulin levels (r = -0.200; P = .018), and homeostasis model assessment-insulin resistance (r = -0.223; P = .009). In the separate analysis for the hypertensive population, sex (P = .014) and homeostasis model assessment-insulin resistance (P = .011) were identified as significant predictors of capillary rarefaction after adjustment for other factors. On the contrary, only HDL levels (P = .036) predicted capillary density in the multiple regression model for the normotensive population. Different aspects of impaired metabolic profile, that is, insulin resistance and low HDL levels, but not angiogenic or inflammatory markers, appear to be independently associated with capillary rarefaction in hypertensive and normotensive individuals.
Copyright © 2016 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Capillary rarefaction; hypertension; insulin resistance; metabolic profile

Mesh:

Substances:

Year:  2016        PMID: 27265366     DOI: 10.1016/j.jash.2016.04.007

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  5 in total

Review 1.  ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on 'coronary microvascular dysfunction in cardiovascular disease'.

Authors:  Teresa Padro; Olivia Manfrini; Raffaele Bugiardini; John Canty; Edina Cenko; Giuseppe De Luca; Dirk J Duncker; Etto C Eringa; Akos Koller; Dimitris Tousoulis; Danijela Trifunovic; Marija Vavlukis; Cor de Wit; Lina Badimon
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 10.787

2.  Oxygen therapy, capillary rarefaction and blood pressure rise in premature low birth weight infants: is there a link?

Authors:  Panagiota Anyfanti; Eugenia Gkaliagkousi; Stella Douma
Journal:  J Hum Hypertens       Date:  2019-10-21       Impact factor: 3.012

3.  Capillary rarefaction from the kidney point of view.

Authors:  Baris Afsar; Rengin E Afsar; Tuncay Dagel; Ege Kaya; Suat Erus; Alberto Ortiz; Adrian Covic; Mehmet Kanbay
Journal:  Clin Kidney J       Date:  2017-11-28

Review 4.  Estrogen Contributions to Microvascular Dysfunction Evolving to Heart Failure With Preserved Ejection Fraction.

Authors:  Ariane A Sickinghe; Suzanne J A Korporaal; Hester M den Ruijter; Elise L Kessler
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-03       Impact factor: 5.555

Review 5.  Invasive Assessment of Coronary Microvascular Function.

Authors:  Fabio Mangiacapra; Michele Mattia Viscusi; Giuseppe Verolino; Luca Paolucci; Annunziata Nusca; Rosetta Melfi; Gian Paolo Ussia; Francesco Grigioni
Journal:  J Clin Med       Date:  2021-12-31       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.